Effect of Bisphosphonates on Function and Mobility Among Children with Osteogenesis Imperfecta: A Systematic Review by Constantino, Christopher et al.
Marquette University 
e-Publications@Marquette 
Library Faculty Research and Publications Library (Raynor Memorial Libraries) 
2019 
Effect of Bisphosphonates on Function and Mobility Among 
Children with Osteogenesis Imperfecta: A Systematic Review 
Christopher Constantino 
Marquette University 
Joseph Krzak 
Shriners Hospital for Children 
Alissa Fial 
Marquette University, alissa.fial@marquette.edu 
Karen M. Kruger 
Marquette University 
Jacob Rammer 
Marquette University 
See next page for additional authors 
Follow this and additional works at: https://epublications.marquette.edu/lib_fac 
Recommended Citation 
Constantino, Christopher; Krzak, Joseph; Fial, Alissa; Kruger, Karen M.; Rammer, Jacob; Radmanovic, 
Katarina; Smith, Peter A.; and Harris, Gerald F., "Effect of Bisphosphonates on Function and Mobility 
Among Children with Osteogenesis Imperfecta: A Systematic Review" (2019). Library Faculty Research 
and Publications. 109. 
https://epublications.marquette.edu/lib_fac/109 
Authors 
Christopher Constantino, Joseph Krzak, Alissa Fial, Karen M. Kruger, Jacob Rammer, Katarina 
Radmanovic, Peter A. Smith, and Gerald F. Harris 
This article is available at e-Publications@Marquette: https://epublications.marquette.edu/lib_fac/109 
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ABSTRACT
Osteogenesis imperfecta (OI) is a rare genetic connective tissue disorder that results in bone fragility and deformity. Management
is multidisciplinary. Although pharmacologic intervention with bisphosphonates (BP) is a standard of care for individuals with
severe OI, no consensus or reviews were found that focus on the effects of bisphosphonates on function and mobility. PubMed,
CINAHL, Cochrane Library, Web of Science, and PEDro databases were searched for eligible articles for this review. Methodological
quality was assessed using the Cochrane Collaboration’s tool for risk of bias. Twenty‐six studies (801 children) were reviewed and
five showed a low risk of bias. Included studies showed significant variability among clinical protocols for administering BP.
Randomized controlled trials did not demonstrate a significant improvement in function and mobility with oral BP administration,
whereas nonrandomized open‐label uncontrolled studies demonstrated that oral and intravenous BP administration objectively
improved function and mobility. The most common outcome measure used by the studies included in this review was the Bleck
score. Effect sizes (d = 0.28 to 4.5) varied among studies. This systematic review also summarized the apparent confounding
variables affecting results of previous studies and provided suggestions to improve the quality of future studies. © 2019 The
Authors. JBMR Plus is published by Wiley Periodicals, Inc. on behalf of the American Society for Bone and Mineral Research.
KEY WORDS: OSTEOGENESIS IMPERFECTA; PAMIDRONATE; ALENDRONATE; ZOLEDRONIC ACID; OLPADRONATE; BLECK; PEDI
Introduction
Osteogenesis imperfecta (OI) is a rare, clinically hetero-genous genetic connective tissue disorder marked by
low bone mass and increased bone fragility, resulting in in-
creased susceptibility to fractures, deformities, and sub-
stantial growth abnormalities.(1) It has a reported incidence
of 1 per 10,000 to 20,000 births.(1–5) Early genetic studies on
OI documented that it is commonly caused by autosomal
dominant heterozygous mutations in one of the two genes
encoding type I collagen, COLIA1 and COLIA2, and recently,
mutations in other genes were documented to be involved
in its pathogenesis.(1–5) With variable clinical manifestations,
OI was initially classified into four types based on severity of
signs and symptoms using the Sillence classification system:
types I and IV being mild and moderate, type II being lethal,
and type III being severe and progressively deforming.(6,7)
Recent studies have broadened the classification of OI into
up to 19 types based on the genes involved.(5,8–10) The
classification system by Sillence is still being used in a
modified fashion in current studies to stratify subject pop-
ulations.(11–14) As a consequence of the physical impairments
brought about by OI, varying degrees of pain,(11,12) gait de-
viations,(13) and functional limitations(11–14) have also been
reported depending on the type and severity of OI. Lower
mobility scores,(11–13) limited performance of activities of
daily living,(12) and lower levels of participation in sports,
exercise, or physical function(11–13) have been reported in
individuals with OI. Despite limitations in functional activity,
studies show individuals with OI are still able to participate
and ambulate in the community but may show difficulty
keeping up with typically developing peers.(12–14)
Without a genetic cure for OI, management of the disease is
aimed at symptom reduction through a multidisciplinary
approach consisting of pharmacologic agents, orthopedic
interventions, physiotherapy, and rehabilitation.(15,16) Among
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pharmacologic interventions, bisphosphonates (BP) have been
considered standard of care for children with severe OI.(17–20)
BP can be administered orally or intravenously with varied ef-
ficacy, and there are two types, both acting on osteoclasts (cells
that break down bone tissue) by disrupting their formation
(nitrogenous type BP) or initiating their apoptosis (non‐
nitrogenous type BP).(19,21)
Although BP therapy is widely used to treat OI, results on
improvements to function and mobility outcomes have been
variable.(22–24) Previously published systematic reviews and
meta‐analyses on BP focused on their effects on increasing
bone mineral density and reducing fracture rate. The reports
mention function and mobility outcomes, but these were
considered secondary variables of interest.(16,25–27) To the
best of our knowledge, no consensus or systematic reviews
have been published to quantitatively describe how BP
therapy affects measures of function and mobility among
individuals with OI.(12–14) Therefore, the purpose of the cur-
rent work was to systematically review existing literature and
describe the effects of BP therapy on improving measures of
function and mobility.
Materials and Methods
Inclusion criteria
Included studies were limited to populations involving male
and female children who have an established diagnosis of OI in
which at least one of the outcomes was the effect of bi-
sphosphonates on function and/or mobility using objective
outcome measures. Studies that included quality‐of‐life (QOL)
or well‐being as outcomes were included if objective parame-
ters of function and mobility were included in the measuring
tools used in those studies. Randomized controlled trials (RCTs),
non‐randomized open‐label uncontrolled studies (NROs), NROs
with a historic control group, and retrospective studies were
included. Non‐randomized open‐label uncontrolled studies are
defined as studies that are not randomized, all subjects
are given treatment (no control or placebo group), and both
the researchers and subjects are aware of the treatment ad-
ministered (no blinding).
Search strategy
We searched the following electronic databases: PubMed, CI-
NAHL (Cumulative Index to Nursing and Allied Health Pro-
fessions), Cochrane Library (Cochrane Database of Systematic
Reviews, Cochrane Central Register of Controlled Trials), Web of
Science, and PEDro (Physiotherapy Evidence Database). The
initial search strategy was developed in PubMed, using a
combination of Medical Subject Terms (MeSH) and key words.
Once the initial search was determined, it was modified to fit
the parameters of the other databases.
Selection of studies and data extraction
The two lead authors (CSC and JJK) screened the articles for
eligibility independently. In the event of disagreement, a third
reviewer (KMK) was included in the discussion until a consensus
was reached. A standardized data extraction form was created
during study selection and was used to compile relevant de-
scriptive information and relevant data among the included
studies.
Strategy for data synthesis
The reviewers provided a narrative synthesis of the findings
from the included studies, structured around OI population
type, route (oral or intravenous), dosage of BP administered,
and outcomes used to measure function and mobility. Based
on the anticipated heterogeneity of outcomes and data com-
pleteness, the reviewers provided a summary of intervention
effects for each study (Table 1). Effects of BP on measures of
function and mobility were calculated with standardized mean
differences on each outcome and effect size when applicable.
Risk of bias (methodological quality) assessment
The two primary reviewers (CSC and JJK) assessed the meth-
odological quality (risk of bias) of the articles independently
using the adapted version of the Cochrane Collaboration’s tool.
This tool reviews five domains, with 11 items. Each item was
scored “1” if the item was present in the article, and “0” if it was
not (Table 2). Studies fulfilling six or more items were regarded
as having a low risk of bias.(28,29) Disagreements were resolved
by including three reviewers (KMK, JRR, and KR) in the dis-
cussion until a consensus was reached. The strength of inter-
rater agreement was measured using Cohen’s Ƙ coefficient
(95% confidence interval), with Ƙ = 0.41 to 0.60 indicating
moderate agreement, Ƙ = 0.61 to 0.80 indicating good agree-
ment, and Ƙ ≥ 0.81 indicating very good agreement.(28,29)
Analysis of subgroups or subsets
Subgroup analyses were performed based on the route of
administration (oral or intravenous) of BP, function and mobi-
lity outcome measure used, and population.
Results
Figure 1 illustrates the article selection process. The search strategy
yielded 423 articles. Removing duplicates, the number was re-
duced to 210, and 173 were excluded based on title and abstract.
Full texts of the 37 remaining articles were screened, and one was
excluded because some participants were given growth hormone
in addition to pamidronate, and the results obtained from these
participants were not differentiated from those who received pa-
midronate only.(30) Two more were excluded because the main
intervention was not bisphosphonate administration.(31,32) Six
more were excluded because the outcomes used were not ob-
jective.(33–38) Two more were excluded because they were found to
be abstracts presented in proceedings.(39,40) A total of 26 full‐text
articles (801 male and female children) including four RCTs,(23,41–43)
17 NROs,(44,45,47,48,50–55,57,58,60–64) three NROs with a historic control
group,(49,56,59) and two retrospective studies(46,65) met the inclusion
criteria and were included. Population sizes (n) ranged from
n= 4(65) to n= 139.(42) Three NROs did not specify sex dis-
tribution.(48,51,63) OI types recruited by most of the studies were I,
III, and IV. Other NROs included participants with types V,(64) VI,(57)
VII,(65) and VIII.(53) Two NROs did not specify the OI type of their
population.(50,60) Two studies included participants with un-
classified types in addition to types I, III, and IV.(42,54) One of the
retrospective studies recruited only females.(65) Bleck score (in-
cluding its modified forms)(66,67) was the most common outcome
tool used in 19 (73%) studies, followed by the pediatric disability
inventory (PEDI),(68) used in six (23%) studies.
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Risk of bias (methodological quality) assessment
Summary of scores of the adapted Cochrane Collaboration’s
tool is shown in Table 2. Interrater agreement was very good
(Ƙ = 0.94). Five studies scored ≥6 (low risk of bias).(23,41–43,59)
Studies demonstrating a positive effect of
bisphosphonates on function and mobility
Oral bisphosphonate administration
Two NROs administered oral alendronate on patients with OI types
I, III, and IV.(52,62) Cho and colleagues(52) measured function and
mobility in 16 patients using a scale the researchers devised
themselves. This scale was a 9‐point scale, with a highest possible
score of 1 (able to sprint and participate in contact sports) and a
lowest possible score of 9 (wheelchair‐ or bedridden; always re-
quiring assistance from others, including self‐care activities). Seven
of their patients had surgical or implant‐related problems that may
have affected their ambulatory/mobility status. Of the remaining
nine that did not have problems, five had improved scores on
latest follow‐up. Vyskocil and colleagues(62) used Bleck scores of 30
patients and reported significant improvement in mobility (2.57 ±
1.15 to 3.68 ± 0.95 after 3 years; p= 0.00001) with an effect size
(Cohen’s D, d) of 2.39.
Intravenous bisphosphonate administration
Most of the studies (69%) included in this review(44–51,54–60,63–65)
used intravenous pamidronate, administered at varying doses,
with durations ranging from 2 to 8 hours over 1 to 3 consecutive
days every 3 to 6 months, administered between 1 and 10 years
based on the participants’ needs. Table 1 shows detailed dosages
and treatment regimens used by each study.
Bleck score: Adiyaman and colleagues(44) found significant
increases with a large effect size among their population
(n = 8), all having Bleck scores of 0 at baseline, increasing to
a mean score of 3.38 ± 1.06 after 1 year of treatment (d = 4.50).
Oztemur and colleagues(46) administered treatment at varying
doses and all showed varying increases in scores (Table 1).
Alharbi and colleagues(47) showed improvement in 27
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Table 2. Risk of Bias (Methodological Quality) Assessment
Study A B C D E F G H I J K Total
Adiyaman et al.(44) 0 0 0 0 0 1 0 0 1 1 1 4
Alharbi et al.(47) 0 0 0 0 0 1 0 0 1 1 0 3
Astrom et al. (2002)(48) 0 0 0 0 0 1 0 0 1 1 1 4
Astrom et al. (2007)(49) 0 0 0 0 0 1 1 0 1 1 1 5
Atta et al.(50) 0 0 0 0 0 1 0 0 1 1 1 4
Bajpai et al.(51) 0 0 0 0 0 1 0 0 1 1 0 3
Cheung et al.(65) 0 0 0 0 0 1 0 0 1 1 1 4
Cho et al.(52) 0 0 0 0 0 1 0 0 1 1 0 3
Falk et al.(45) 0 0 0 0 0 1 0 0 1 1 0 3
Garganta et al.(53) 0 0 0 0 0 0 0 0 1 1 1 3
Glorieux et al.(54) 0 0 0 0 0 1 0 0 1 1 0 3
Goksen et al.(55) 0 0 0 0 0 1 0 0 1 1 0 3
Kok et al.(41) 1 1 1 1 0 1 1 0 1 1 1 9
Land et al. (2006)(58) 0 0 0 0 0 1 1 0 1 1 1 5
Land et al. (2007)(57) 0 0 0 0 0 1 1 0 1 1 0 4
Lowing et al.(58) 0 0 0 0 0 1 0 0 1 1 1 4
Munns et al.(59) 0 0 0 0 0 1 1 1 1 1 1 6
Oztemur et al.(46) 0 0 0 0 0 1 0 0 1 1 0 3
Sakkers et al.(23) 1 1 1 1 1 1 1 1 1 1 1 11
Salehpour et al.(60) 0 0 0 0 0 1 0 0 1 1 0 3
Sanchez‐Sanchez
et al.(61)
0 0 0 0 0 1 0 0 0 1 0 2
Seikaly et al.(43) 1 1 1 1 1 1 1 0 1 1 1 10
Vyskocil et al.(62) 0 0 0 0 0 1 0 0 1 1 1 4
Ward et al.(42) 1 1 1 1 1 1 1 1 1 1 1 11
Zacharin et al.(63) 0 0 0 0 0 1 0 0 1 1 1 4
Zeitlin et al.(64) 0 0 0 0 0 1 1 0 1 1 0 4
A = adequate randomization; B = concealed treatment allocation;
C = patients blinded; D = care providers blinded; E = outcome as-
sessors blinded; F = drop‐out described and acceptable; G = par-
ticipants analyzed in allocated groups; H = groups similar at
baseline; I = cointerventions avoided or similar; J = acceptable
compliance in all groups; K = similar timing of outcome assessment
in all groups.
Fig. 1. Article selection process.
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participants from 1.8 ± 1.7 to 2.9 ± 1.5 (p = 0.01, d = 0.78). Atta
and colleagues(50) reported improved scores from 0.94 ± 1.30 to
2.5 ± 1.02 (p < 0.001, d = 1.03) among 72 patients. Bajpai and
colleagues(51) noted improvement from 1.36 ± 1.12 to
2.53 ± 1.18 (d = 1.23) among 17 participants. Astrom and col-
leagues(48) measured mobility using the Wilson scale (un-
published scale used in Sweden that has a highest score of
1 and lowest of 9) and the Bleck score. They reported im-
provements in both outcome measures (Bleck: 0.68 ± 1.22 to
1.57 ± 1.26; Wilson: 7.04 ± 2.50 to 4.86 ± 2.65), with effect size
smaller on the Bleck scores (d = 0.28) compared with the Wilson
scale (d = 0.91).(48) Land and colleagues performed two studies
in 2006(56) and 2007.(57) In their earlier study, they reported
changes from baseline Bleck scores among 59 patients who
received 3 years of intravenous BP. Their results showed in-
creased scores from baseline (0.84 ± 1.19 to 1.90 ± 1.25 after
3 years of treatment; p < 0.001, d = 0.58). In their later study,(57)
they compared Bleck scores among 10 patients with OI type VI
versus age‐ and disease severity‐matched patients with types I,
III, and IV. They found increased scores after treatment in both
groups but with lower scores among type VI patients compared
with those with types I, III, and IV (2.9 ± 1.2; p < 0.05, d = 1.42
versus 3.8 ± 0.4; p < 0.05, d = 7.29). Zeitlin and colleagues(64)
compared scores among 11 patients with OI type V versus age‐
and disease severity‐matched patients with types I, III, and IV,
and reported improved scores among type V patients 2.7 ± 1.7
at baseline to 3.3 ± 1.3 after treatment (p < 0.05, d = 0.83). The
scores of these patients were lower than the control group of
types I, III, and IV that had baseline and post‐treatment means
of 3 and 4, respectively. Cheung and colleagues(65) retro-
spectively reviewed 4 patients with OI type VII versus age‐ and
disease severity‐matched patients with types I, III, and IV and
reported non‐significant increases in both groups. Glorieux and
colleagues(54) noted improvement in 16 of 30 participants.
Goksen and colleagues(55) noted improvement in 10 of 14
participants. Salehpour and colleagues(60) noted improvement
in 59 of 64 participants. Among the participants who had no
improvement in these three studies, their Bleck scores did not
change and none had reported lower Bleck scores after treat-
ment. Zacharin and colleagues(63) also noted increased Bleck
scores among all their 18 participants. Means and individual
scores were not available in four studies.(54,55,60,63)
PEDI score: Lowing and colleagues(58) reported improvement
in the mobility domain of the functional and caregiver assistance
scales of PEDI after 1 year of treatment in 40 of 43 of their
participants (p < 0.001). Two of the three who did not improve
had recurrent periods with fractures and intramedullary rodding
surgery, whereas the other patient already had maximum scores
at baseline. The earlier study of Land and colleagues(56) reported
a significant increase in PEDI scores after 3 years among the 59
patients with OI types I, III, and IV with similar changes from
baseline among the types (type I: 22.7 ± 18.7, type III: 24.6 ± 14.5,
type IV: 21.9 ± 15.8; analysis of variance: p = 0.59). In their later
study, they reported improvement in PEDI scores among OI type
VI patients, with their scores being lower than those with types I,
III, and IV.(57) Munns and colleagues(59) reported better scores
among those treated with i.v. BP (36 ± 13 versus 24 ± 12 for
controls, p < 0.001, d = 0.95). Cheung and colleagues(65) noted
non‐significant increases in both groups.
Comparison with a historic untreated population: In another
study by Astrom and colleagues,(49) they compared Bleck and
Wilson scores of patients who received intravenous pamidronate
to scores of a historical untreated group. Better scores were found
among patients who received treatment on both Bleck (3.0 ± 0.77
versus 0.36 ± 0.67 for controls; p< 0.001, d= 3.63) and Wilson
(2.82 ± 2.09 versus 7.45 ± 1.51 for controls; p< 0.001, d = 2.55)
scores.(49) In their 2006 study, Land and colleagues(56) compared
historic data from 48 untreated patients and compared their
scores to 48 age‐matched patients who received treatment for
3 years. Their results showed significantly higher Bleck scores
among the treatment group (2.1 ± 1.2) versus untreated
(1.0 ± 1.2), p= 0.001. The mobility domain of PEDI was also sig-
nificantly higher among the treatment group (76.3) versus un-
treated (58.3), p= 0.002. Munns and colleagues(59) showed
increased Bleck scores among 58 treated patients compared with
an age‐matched historical untreated control group (2.3 ± 1.0
versus 0.8 ± 1.0; p< 0.001, d = 0.75).
Intravenous zoledronic acid administration: Garganta and
colleagues(53) used both pamidronate (1.1 mg/kg/d every
3 months for patients 2 to 3 years old; 1.5 mg/kg/d every
4 months for patients aged >3 years old) and zoledronic acid
(0.05 mg/kg/d every 6 months) to treat 22 children with OI types
I, III, IV, and VIII and used the Pediatric Quality of Life Inventory
4.0 Generic Core Scales for Physical Functioning (PedsQL)(69) to
measure physical function. The choice of BP was based on what
regimen the patients were already taking at the start of the
study. Not all patients in this study were able to complete study
visits, and only 5 patients had data on all visits. These patients
had significant changes in scores from the first visit to the post‐
visit with mean PedsQL scores of 49.48 ± 25.49 before infusion
and 57.03 ± 25.29 after 4 weeks post‐infusion (p = 0.007,
d = 1.24). Physical function improved after the first infusion and
diminished to pre‐infusion levels during the time of the next
infusion. Mean score was 46.88 ± 28.13 by the second infusion
(p = 0.008, d = 0.51). There were no significant differences be-
tween patients treated with pamidronate and zoledronic acid
with respect to age, sex, or OI type. Sanchez‐Sanchez and col-
leagues(61) treated 14 children with OI types I, III, and IV with
zoledronic acid 0.05 mg/kg administered over 1 to 2 hours every
6 months with varying treatment durations. The study used the
modified Bleck score (9‐point scale) and noted improved mean
scores of 4 at pretreatment and 6 after treatment (p = 0.001).
Studies demonstrating no effect on function and
mobility
All RCTs used oral BP including olpadronate 10 mg/m2/d(23,41)
and alendronate 5 mg/d (patients <40 kg) or 10 mg/d (patients
>40 kg).(42,44) Kok and colleagues(41) used the ambulation do-
main of the Health‐utility index‐mark III scale(70) and athletic
performance domain of the Harter self‐perception profile for
children(71) for participants >6 years old to measure function
and mobility. Sakkers and colleagues(22) used both modified
Bleck scores and PEDI. The remaining two RCTs used PEDI.(42,43)
All RCTs reported no significant difference between treatment
and placebo groups. In the 2006 study of Land and col-
leagues,(56) the self‐care domain of PEDI (measure of function)
was not significant between the two groups. Falk and col-
leagues(45) also noted inconclusive PEDI scores in their study.
Discussion
The purpose of the current work was to systematically review
existing literature describing the effect of BP therapy on
measures of function and mobility. The results of this current
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review show that children given intravenous BP have increased
mobility, as measured by Bleck scores, after treatment. Results
also showed that mobility scores were greater in patients with
OI type I, III, and IV compared with other types. Moreover,
based on the studies by Astrom and colleagues,(49) Land and
colleagues,(56) and Munns and colleagues,(59) improvements are
expected to be significantly greater than one would expect
when compared with a historical untreated population.
All RCTs showed that oral BPs had no significant effect on
function and mobility scores between treatment and placebo
groups. In contrast, two NROs that used oral alendronate noted
improvements in mobility.(52,62) Cho and colleagues(52) used an
unpublished scale that the researchers devised themselves;
hence their findings cannot be compared with those from
other studies included in this review. Vyskocil and colleagues(62)
used the Bleck score, which is the scale most of the studies in
this review used, and it was also used by one of the RCTs
(Sakkers and colleagues(23)). Comparing these studies, pop-
ulation sizes were close (34 for Sakkers and colleagues; 30 for
Vyskocil and colleagues), but these studies differed in terms of
treatment time (Sakkers and colleagues administered for
2 years; Vyskocil and colleagues for 3 years), age group (Sakkers
and colleagues = 10 ± 3.1 years old; Vyskocil and colleagues = 4
to 16 years old), and drug of choice (Sakkers and colleagues
used olpadronate; Vyskocil and colleagues used alendronate).
Between the two studies, Sakkers and colleagues has a lower
risk of bias, scoring 11/11 in the Cochrane Collaboration’s tool,
whereas Vyskocil and colleagues only scored 4/11. All studies
that administered BP intravenously were not randomized and
uncontrolled, and if control groups were included, they were
primarily limited to historical data. The paucity of RCTs in the
available literature can be explained by the fact that intra-
venous BP administration became a standard of care for the
management of severe OI before the RCTs were performed;
thus, including a placebo or untreated control group in a study
of severe OI is problematic. The three studies(49,56,59) that col-
lected data from untreated groups obtained the data earlier
than the data from the treatment groups, and intravenous BP
may have not yet been used during that time. Relatively small
sample sizes among the included studies reflect the rarity of OI.
An improvement in mobility was consistent among all the
NROs that administered intravenous BP and used Bleck
scores (including its modified version) to measure
mobility.(44,47–51,54–57,59–61,63,64) Adiyaman and colleagues(44)
showed a very large effect size (d = 4.5), which can be explained
by all his subjects starting with a score of 0 at baseline. In the
study by Oztemur and colleagues,(46) the varying dosages and
the small sample size reduced the power of the findings, but it
is still important to note that all patients either improved or
retained their baseline mobility scores and none had a decrease
after treatment. Alharbi and colleagues(47) reported a moderate
effect size (d = 0.78), which can be explained by a number of
poor responders to treatment. The overall effect to mobility,
however, was still an increase. The Wilson scale that Astrom
and colleagues used in both their studies is unpublished and
has not been verified or tested for reliability, but since both
studies also used Bleck, findings from both studies also con-
tribute to the overall improved mobility scores found in this
review.(48,49) Moreover, it is consistent in all studies that treat-
ment with i.v. BP does not decrease function or mobility scores.
Another consistent finding in this review is that baseline and
post‐treatment function and mobility scores are higher among
patients with types I, III, and IV compared with other types
(types V,(64) VI,(57) VII(65)) as measured by both Bleck(55,57,64) and
PEDI(57,65) scores. Function and mobility scores measured by
PEDI were inconsistent. Falk and colleagues(45) noted incon-
clusive results and Cheung and colleagues(65) noted non‐sig-
nificant increases in scores, while four other studies(56–59)
reported improvement after i.v. BP administration. In the study
performed by Garganta and colleagues(53) using both i.v. pa-
midronate and zoledronic acid, increased function was noted
with the use of the PedsQL scales, but because this is the only
study that used this scale, no comparisons with other studies
can be made. The retrospective review by Cheung and col-
leagues,(65) which had a sample size of 4 and only included
females, was the only study to show non‐significant increases
in Bleck scores after i.v. BP administration.
Limitations of this review include a high number of studies
(81%) with low methodologic quality. In addition, among the
studies that administered BP intravenously, only one study had
high methodologic quality.(59) This could be explained by the
Cochrane collaboration tool, which was used to appraise the
included studies regarding methodologic quality. As RCTs were
included in this review, an appraisal tool specific to RCTs was
employed. Because of this, any study that was not an RCT is
discredited in five of the 11 categories in the assessment tool.
Additionally, most of the studies included in this review scored
low on the appraisal tool for not having comparable groups at
baseline. This was not because they had different baseline
groups, but because they had no control groups since these
were single‐group studies that tracked changes over time.
These were longitudinal studies that lacked comparison.
Another point, which was expected because of the rarity of
OI, has made the administration of BP, sample sizes, and follow‐
up periods very heterogeneous among the included studies.
Also, because of the wide ranges of age groups and differences
in demographic profiles and OI types, findings in the studies
may not have enough power to draw strong correlations.
Lastly, some studies included in this review may have been
underpowered for outcome measures related to function and
mobility. Most of the included studies were powered based on
a primary outcome of bone mineral density. Therefore, we are
uncertain if sufficient sample sizes were recruited in all studies
to identify an effect of bisphosphonates on the chosen meas-
ures of function and mobility.
Hence, it is advised that our results be interpreted with caution
because of these limitations. We suggest that future studies be
conducted among comparable cohorts at baseline by ensuring
participants with similar ages, OI types, and functional status at
baseline to reduce confounding variables that may affect the
outcome of these studies. Furthermore, these populations should
receive consistent treatment regimens and durations of BP ad-
ministration in order to draw stronger conclusions regarding the
effectiveness of BP administration on improving function and
mobility. Although intravenous BP is the standard of care and
RCTs involving placebo controls are not possible, controlled
studies that compare dosage regimens or combinations of BP
treatment with other modalities like physical therapy are also
suggested. It is suggested that better‐powered studies on the
effect of BP on function and mobility among children with OI be
performed in the future.
This review, however, cannot answer which i.v. BP dosage
best improved mobility because of the heterogeneous studies
included, and future studies with more consistent dosages and
treatment times with bigger and more homogeneous samples
that measure mobility using the Bleck score are suggested.
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